multivesicular bodies (MVB) and the plasma membrane that directs the recycling of transferrin receptors during reticulocyte maturation.
In 1996, exosomes derived from B lymphocytes were found to show antigen-presenting properties, enabling the induction of T-cell responses. 8 Similarly, antigen-presenting exosomes from dendritic cells were also found to suppress cancer progression. 9 Aside from participating in the immune system, comprehensive functions in various pathophysiological processes highlight the importance of exosomes in regulating cancer development and neurodegenerative diseases. 2 
| Characteristics of exosomes
Exosomes are nanoscaled extracellular vesicles (in general, their sizes range from 30 to 150 nm) released by almost all cell types. 2, 4 Within the endosomal network, the biogenesis of exosomes is generated as intraluminal vesicles (ILV, also called pre-exosomes) by inward budding of the multivesicular body membrane. 2 Mechanisms of exosome biogenesis are highly regulated through several distinct pathways, 1 including ESCRT (endosomal sorting complexes required for transport)-dependent and ESCRT-independent pathways ( Figure 1 ). In the F I G U R E 1 Biogenesis of exosomes. First, endocytosis could be mediated by either a clathrin-dependent pathway or a clathrin-independent pathway, which often actively occurs at the lipid raft containing a variety of tumor-specific receptors and signaling proteins (eg, growth factor receptors, oncoproteins) in addition to common membrane proteins, such as tetraspanins (eg, CD9, CD63, CD81), MHC I and II, and adhesion molecules (eg, integrins, cadherins). Using the endosomal network, the biogenesis of exosomes is achieved in an endosomal sorting complexes required for transport (ESCRT)-dependent or ESCRT-independent method. Accordingly, intraluminal vesicles (exosomes) show inward budding of the multivesicular bodies (MVB). Indeed, numerous cytoplasmic (eg, ubiquitin-related proteins, heat shock proteins, microRNAs [miRNAs] , mRNAs, cytoskeleton proteins etc.) and nuclear molecules (eg, transcriptional factors, longnoncoding RNAs [lncRNAs], DNAs etc.) can be selectively loaded into MVB in a cancer type-specific and/or stage-specific way. Furthermore, multivesicular bodies are fused with the plasma membrane, leading to the release of exosomes toward the extracellular space in an exocytic way. Several Rab GTPases, including Rab11/35, Rab7, and Rab27, have been reported to be involved in exosome secretion. Finally, tumor-derived exosomes are transferred to the local tumor microenvironment and distinct organs to regulate tumorigenesis or metastasis, respectively. rER, rough endoplasmic reticulum; sER, smooth endoplasmic reticulum TAI ET AL.
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ESCRT membrane-scission machinery, 4 multiprotein subcomplexes (ESCRT-0, ESCRT-I, ESCRT-II, and ESCRT-III) are required for exosome biogenesis. Early ESCRT complexes (ESCRT-0, ESCRT-I, and ESCRT-III) recognize ubiquitinated cargo by their ubiquitin-binding subunits, leading to the formation of stable protein complexes within the cytoplasm. The ESCRT-III complex then transiently assembles on endosomes and conducts the vesicle scission. 10 Recently, some auxiliary components, including ATPase, vacuolar protein sorting-associated protein (VPS4), or ALG-2-interacting protein X (ALIX), have been indicated to participate in the regulation of ESCRT membranescission machinery. 10 In contrast, the budding or release of exosomes is regulated by lipids, such as sphingolipid ceramide 11 or sphingosine 1-phosphate within the ESCRT-independent pathway. 
| Tumor-derived exosomes in cancer progression
Cancer progression is a dynamic and multistep process in which several well-studied signaling events aid in orchestrating the development of cancer malignancy. Tumor-derived exosomes have been indicated to actively regulate cancer progression by inducing autocrine/paracrine oncogenesis, reprogramming stromal cells, modulating the immune system, while also promoting angiogenesis. 24 Transfer of oncogenic molecules within oncosomes between primary tumor results in morphological transformation and an increase in anchorage-independent growth in recipient cancer cells. 22 Likewise, tumor-derived exosomes exert antiapoptotic effects of TGF-β1 signaling in an autocrine way, which subsequently renders the promotion of cancer proliferation. 33 ZFAS1 lncRNA enclosed within exosomes is transferred from malignant cancers to ZFAS1-negative cancer subpopulations to enhance the proliferation of ZFAS1-negative cancer subpopulations. 23 Through this advantageous paracrine route, some metabolites, such as intermediates of the tricarboxylic acid (TCA) cycle, are often packaged into CAF-derived exosomes and are transferred from CAF to cancer cells. 26 Subsequently, metabolic cargoes carried within exosomes enable glycolysis modulation and glutamine-dependent reductive carboxylation in cancers, contributing to cancer growth. 26 Reciprocally, tumor-derived exosomes regulate F I G U R E 2 Summary of tumor-derived exosome-mediated functions. Tumor-derived exosomes regulate the autocrine/paracrine induction of cancers, activation of angiogenesis, modulation of the immune system, re-education of stromal cells, organotropic metastasis, and remodeling the extracellular matrix, contributing to cancer progression and metastasis. For example, tumor-derived exosomes transfer epidermal growth factor receptor (eEGFR) vIII oncogenic receptor or ZFAS1 lncRNA from aggressive cancers to nonaggressive cancers, inducing cancer progression. Also, tumor-derived exosomes that show tetraspanins or microRNA (miRNA) clusters induce endothelial migration and tube formation. Furthermore, tumor-derived exosomes containing miRNAs, such as miR-222-3p, induce polarization of M2 macrophages. Additionally, tumor-derived exosomes deliver miRNA, such as miR-9, miR-105, and miR-181c, from cancers to normal fibroblasts or vascular endothelial barriers, subsequently enhancing cancer malignancy. Moreover, integrins direct tumor-derived exosomes to specific distinct target organs, leading to metastatic organotropism. By delivery of extracellular matrix remodeling enzymes, tumor-derived exosomes contribute to cancer metastasis 43 Tumor exosomes direct stromal cell reprogramming and can also serve as a critical event driving cancer progression. In this regard, tumor-derived exosomes deliver miRNA, such as miR-9, that gives rise to the differentiation of fibroblasts into CAF with higher cell motility. 36 Moreover, miR-9 is also released from the CAF to enhance cancer progression. 36 Tumor-derived exosomes also trigger differentiation of mesenchymal stem cells (MSC) into myofibroblasts that show pro-angiogenic and pro-invasive characteristics. 32 The differentiated MSC then further promote cancer proliferation and invasion by secreting growth factors and matrix-regulating factors. exosome-mediated MET oncoprotein. 31 Recently, the same group further indicated that integrin expression profiles of tumor-derived exosomes function as "ZIP codes" to direct exosomes to specific tissues/organs, leading to metastatic organotropism. 30 In light of proteomics and clinical relevance analyses, exosomal integrins α6β4 and α6β1 were positively correlated with lung metastasis, whereas exosome integrin αvβ5 was highly associated with liver metastasis. 30 Furthermore, tumor-derived exosomes induced the activation of Src and caused an upregulation of pro-inflammatory S100 genes in the recipient cells of target organs, leading to the establishment of premetastatic niches. 29 In addition, enormous numbers of exosomes were found to be released from CAF during chemotherapy. 35 Presumably, it is believed that such change is to promote survival, proliferation, and drug resistance of cancer cells, in part as a result of increased expression of chemoresistance-inducing factor, Snail. 35 Moreover, exosomes from TAM diminish chemotherapy sensitivity of cancers as a result of miR-21 activity. 38 These studies suggested that exosomes derived from tumor microenvironments play an active and essential role in the regulation of cancer chemo-and/or radiation resistance. 
| EXOSOMES IN CLINICAL APPLICATIONS

| Tumor exosomes as potential biomarkers
Cancer is actively evolving over time through each mutation and selection process that further promotes its malignancy. Being once removed from its parental cells, exosomal cargoes bare strong resemblance to the intracellular status of the original secreted cell.
Thus, real-time detection of the changes within exosomal cargoes could provide insightful information for the fundamental prerequisite of precision medicine in terms of diagnosis, prognosis, and disease monitoring ( Table 2 ). For example, early detection of cancer substantially improves the odds for successful therapeutic outcome and enhances survival rate; therefore, the unmet need for sensitive and precise biomarkers is vital. Advantages of identifying tumor markers within liquid biopsies are that it is minimally invasive, easily obtained, and rapid and economical relative to tissue biopsies. Moreover, the vast amount of dynamic information readily extracted from a patient is valuable in aiding identification of early detection biomarkers in cancer patients. In particular, lipid-based exosomes provide a more robust and enriched vehicle for vulnerable biological molecules in circulating fluids, such as serum, plasma, urine, and saliva. The stability of biological molecules in exosomes derived from blood plasma is high (over 90 days) under general storage conditions. 56 Moreover, the number of exosomes in body fluids is often found to be significantly higher in patients with disease. 56 To be noted, despite rapid clearance processes are commonly observed in liver or kidney, implying a poor understanding of the stability and pathogenicity of cfDNAs. 57 Circulating tumor cells are extremely rarely observed in peripheral blood. Thus, to isolate and identify these rare circulating tumor cells among all other hematopoietic and immune cells is rather difficult and an effective isolating and detection approach is urgently needed. 58 Recently, we found that specific integrin expression profiles of tumor-derived exosomes could function as "ZIP codes" that direct organotropic metastasis. 30 This is the first bioactive molecule that predicts organ-specific metastases of cancers, attributing to exosomal integrins as biomarkers of organotropic metastatic potential. 30 Similarly, a specific exosome signature, including tyrosinase-related protein-2 (TYRP2), very late antigen 4 (VLA-4), heat shock protein 70 (HSP70), HSP90 isoform, and MET, was identified to be abundantly expressed during the late stage of melanoma, serving as an alternative diagnosis of aggressive melanoma using liquid biopsies. 31 Clinically, exosomes derived from serum samples of patients with glioblastoma bear specific EGFR VIII, reinforcing tumor-derived exosomes as sources of biomarkers reflecting the status of parental cancer cells. 54 In addition, specific gene expressions of exosomes in urine are correlated with patients having high-grade prostate cancer, which sheds light on the advantages of exosomes in the diagnosis and prognosis of cancer development. 55 In contrast, androgen receptor splice variant 7 RNA expression in exosomes derived from patients with metastatic prostate cancer highly predicts the development of endocrine therapy resistance. 53 Together, these basic and clinical studies imply a potential role of exosomes in disease prognostication.
| Tumor exosomes as therapeutic targets
Cargoes of tumor-derived exosomes attribute to cancer development. Thus, alternative therapeutic strategies, such as blockage of exosome production, secretion, and exosome-mediated cell-cell communication, as well as ablation of specific active exosomal cargos, have been proposed as novel cancer interventions (Table 3) . Indeed, inhibition of the ESCRT-dependent or the ESCRT-independent mechanism-mediated exosome biogenesis, such as syndecan/syntenin/ALIX signaling 60 or sphingomyelinases, 11 respectively, has shown detrimental effects in exosome production and on cancer progression.
Another critical protein significant in exosome secretion, Rab27 small GTPase, is involved in regulating the docking of multivesicular endosomes onto the plasma membrane and the size of multivesicular endosomes. 61 Cancer proliferation and metastasis were hindered upon inhibiting Rab27a. 45 An inhibitor of clathrin-mediated endocytosis, chlorpromazine, was shown to impede cancer malignancy in vitro by targeting the mechanism of exosome uptake by endocytosis or macropinocytosis. 62 Furthermore, the surface proteins of tumor-derived exosomes display specific glycosylation patterns that are involved in the regulation of exosome uptake by recipient cells. 59 Such a finding suggests that alteration in the glycosylation of exosomal proteins can be potent in cancer progression. Recently, a cancer treatment strategy for extracorporeal hemofiltration of exosomes from the circulation by an affinity plasmapheresis platform has been proposed, 63 suggesting that removal of exosome from the circulatory system provides an additional strategy for therapeutic reagents to block the oncogenic signal on cancers. Together, these studies suggest that various potential therapeutic strategies by intercepting biogenesis, secretion, or uptake of tumor-derived exosomes are promising means for the development of anticancer therapies.
| Roles of tumor exosomes in drug resistance
Drug resistance in cancer occurs from tumor exosomes through a drug efflux-dependent mechanism by pumping chemotherapeutic 
| Roles of exosomes in drug delivery
Resembling liposomes, naturally secreted exosome vesicles have garnered much attention as drug-delivery vehicles. First of all, the nanometric-sized exosomes can be easily transferred between cells.
Second, the lipid bilayer-membrane structure of exosomes confers a protected environment for bioactive molecules from degradation in the extracellular milieu. 3 Third, exosomes show lower immunogenicity and toxicity than other drug-delivery strategies. 74 Last, exosomes bearing specific surface proteins, such as integrins, can direct themselves to specific organs. 30 These features of exosomes implicate that exosomes can be efficient drug-delivery vesicles for the delivery of anticancer agents, siRNAs, or proteins (Table 3) . Interestingly, exosomes transfer anticancer drugs through the BBB, leading to cytotoxic effects in Danio rerio brain cancers. 64 Prevalently, exosomes loaded with anticancer drug derived from autologous cancers can be taken up by parental cancer cells through endocytosis, leading to increased cytotoxicity in parental cancer cells. 65 In terms of targeting specificity, αv integrin-specific RGD (Arg-Gly-Asp) peptide was fused on exosomes loaded with anticancer drug (ie, doxorubicin) to significantly improve exosome uptake by αv integrin-positive cancer cells, leading to inhibition of cancer growth. 66 Intrinsically, exosomes have been recognized as novel cell-free vaccines in immunotherapy. 9 Cancer antigens loaded into exosomes derived from autologous dendritic cells facilitate anticancer immune responses (ie, induced natural killer, NK, cell effector functions) in patients with advanced non-small-cell lung cancer. 67 Further study used exosomes from interferon-γ-mature dendritic cells to accelerate anticancer immune responses in both NK and T cells. 68 Increase in NK cell activity and longer progression-free survival rate were observed in patients with advanced non-small-cell lung cancer. 68 Together, these studies suggested that exosomes function as potential drug-delivery vehicles or cell-free vaccines in anticancer therapies.
| CONCLUSION
Normal cell homeostasis relies upon the exchange of biological materials across the membranes and such transport is facilitated through vesicles that compartmentalize cargo to its appropriate destination. 
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